Literature DB >> 3462404

Endogenous sex hormones, prolactin, and breast cancer in premenopausal women.

F Meyer, J B Brown, A S Morrison, B MacMahon.   

Abstract

Forty-one women with breast cancer and 119 controls participated in a case-control study of the relation of endogenous sex hormones to breast carcinoma in premenopausal women. During the follicular phase of the menstrual cycle, one overnight urine specimen was collected. During the luteal phase, urine and blood specimens were obtained. 17 beta-Estradiol, sex hormone-binding globulin, progesterone, and prolactin were measured in plasma, whereas estrogen metabolites (estrone, estradiol, and estriol) and pregnanediol were assessed in the urine. Breast cancer was associated with high-plasma estradiol and prolactin and with low progesterone. Similar but weaker associations were observed for urinary estrogens and pregnanediol in the luteal phase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3462404     DOI: 10.1093/jnci/77.3.613

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  14 in total

Review 1.  The international variation in breast cancer rates: an epidemiological assessment.

Authors:  B E Henderson; L Bernstein
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

2.  Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies.

Authors:  L Bernstein; J M Yuan; R K Ross; M C Pike; R Hanisch; R Lobo; F Stanczyk; Y T Gao; B E Henderson
Journal:  Cancer Causes Control       Date:  1990-07       Impact factor: 2.506

Review 3.  Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.

Authors:  Carlo Campagnoli; Françoise Clavel-Chapelon; Rudolf Kaaks; Clementina Peris; Franco Berrino
Journal:  J Steroid Biochem Mol Biol       Date:  2005-07       Impact factor: 4.292

Review 4.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

5.  Circulating prolactin levels and risk of epithelial ovarian cancer.

Authors:  Tess V Clendenen; Alan A Arslan; Anna E Lokshin; Mengling Liu; Eva Lundin; Karen L Koenig; Franco Berrino; Goran Hallmans; Annika Idahl; Vittorio Krogh; Annekatrin Lukanova; Adele Marrangoni; Paola Muti; Brian M Nolen; Nina Ohlson; Roy E Shore; Sabina Sieri; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

6.  The relation of reported alcohol ingestion to plasma levels of estrogens and androgens in premenopausal women (Maryland, United States).

Authors:  J F Dorgan; M E Reichman; J T Judd; C Brown; C Longcope; A Schatzkin; W S Campbell; C Franz; L Kahle; P R Taylor
Journal:  Cancer Causes Control       Date:  1994-01       Impact factor: 2.506

7.  Exposure, susceptibility, and breast cancer risk: a hypothesis regarding exogenous carcinogens, breast tissue development, and social gradients, including black/white differences, in breast cancer incidence.

Authors:  N Krieger
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

8.  Season of tumour detection influences factors predicting survival of patients with breast cancer.

Authors:  B H Mason; I M Holdaway; A W Stewart; L M Neave; R G Kay
Journal:  Breast Cancer Res Treat       Date:  1990-01       Impact factor: 4.872

Review 9.  Prolactin and breast cancer etiology: an epidemiologic perspective.

Authors:  Shelley S Tworoger; Susan E Hankinson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-02       Impact factor: 2.673

10.  Prolactin levels, breast-feeding and milk production in a cohort of young healthy women from high-risk breast cancer families: implications for breast cancer risk.

Authors:  Maria Hietala; Håkan Olsson; Helena Jernström
Journal:  Fam Cancer       Date:  2007-12-15       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.